Illustration of a liver protected from lymphoma and Hepatitis B by antiviral medication.

Hepatitis B and Lymphoma: Can Antiviral Drugs Prevent Reactivation?

Nico Varela monogram
Nico Varela in Health & Wellness October 2026 • 4 min read.

"A new study investigates the effectiveness of Tenofovir versus Lamivudine in preventing Hepatitis B reactivation in lymphoma patients undergoing chemotherapy."


For individuals battling lymphoma who are also carriers of the hepatitis B virus (HBV), the road to recovery can be fraught with complications. Chemotherapy, while crucial for treating lymphoma, can inadvertently trigger HBV reactivation, leading to severe liver damage and potentially life-threatening outcomes. This phenomenon has spurred researchers to investigate effective strategies for preventing HBV reactivation in these vulnerable patients.

Antiviral prophylaxis, the preventive use of antiviral medications, has emerged as a promising approach to mitigate the risk of HBV reactivation in lymphoma patients undergoing chemotherapy. Among the various antiviral agents available, tenofovir and lamivudine have garnered significant attention for their efficacy in suppressing HBV replication. However, questions remain regarding which drug offers superior protection and whether their benefits outweigh the potential risks.

A recent study published in the journal Blood has shed light on this critical issue, comparing the effectiveness of tenofovir and lamivudine in preventing HBV reactivation in patients with advanced-stage diffuse large B-cell lymphoma (DLBCL). The study's findings offer valuable insights for clinicians and patients alike, providing evidence-based guidance on the optimal antiviral prophylaxis strategy for this high-risk population.

AI Search Multiple angles on this topic

HBV Across B-Cell Lymphoma Subtypes

A 2024 analysis of 1,424 patients reported similar HBV infection rates in aggressive and indolent B-cell non-Hodgkin lymphoma (B-NHL): 8.30% and 7.88%, respectively. The highest rates were reported in diffuse large B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. The study found no significant differences in clinical characteristics, progression-free survival, or overall survival between HBV-positive and HBV-negative patients in the analyzed B-NHL subtypes. CDC’s HepTracker provides U.S. viral hepatitis case-surveillance and mortality data, including for hepatitis B, to help monitor trends and public-health progress.

Discovery and Research Milestones

A 2014 history of hepatitis milestones describes the discovery of hepatitis viruses as a scientific journey marked by breakthroughs that reshaped medicine and public health. It highlights HBV’s discovery as the starting point for development of the hepatitis B vaccine, described as the first vaccine not prepared by tissue culture. Later research has examined the clinical and scientific evidence linking HBV with B-cell lymphoma, particularly diffuse large B-cell lymphoma (DLBCL). Research on B-NHL pathogenesis also describes germinal-center-origin lymphomas as accounting for 80% of NHL, including DLBCL, follicular lymphoma, and Burkitt lymphoma.

Tenofovir vs. Lamivudine: Which Antiviral Reigns Supreme?

Illustration of a liver protected from lymphoma and Hepatitis B by antiviral medication.

The study, conducted at the Hematology Unit of the Federico II University of Naples, Italy, enrolled 77 patients with advanced-stage DLBCL who were also HBV carriers. The participants were divided into two groups: one receiving tenofovir prophylaxis and the other receiving lamivudine prophylaxis. Researchers then closely monitored both groups for HBV reactivation, liver damage, and other adverse events during and after chemotherapy.

The results revealed a striking difference between the two antiviral agents. None of the patients in the tenofovir group experienced HBV reactivation, whereas 15 patients in the lamivudine group developed the complication. This translates to an absolute risk reduction of 39.5% with tenofovir, indicating a significantly lower likelihood of HBV reactivation compared to lamivudine.

  • Superior Efficacy: Tenofovir demonstrated a clear advantage over lamivudine in preventing HBV reactivation.
  • Reduced Liver Damage: The tenofovir group experienced fewer cases of acute hepatitis, a severe form of liver inflammation, compared to the lamivudine group.
  • Chemotherapy Completion: Patients receiving tenofovir were less likely to experience disruptions in their chemotherapy treatment due to HBV-related complications.
AI Search Multiple angles on this topic

Limits of Prophylaxis Evidence

In a randomized prospective study of patients with hematologic malignancies receiving rituximab-based regimens, tenofovir disoproxil fumarate (TDF) showed a non-significant trend toward preventing HBV reactivation. Guidelines from EASL and AASLD recommend anti-HBV prophylaxis for patients receiving rituximab, but the optimal duration remains uncertain; reported durations range from 6 to 18 months after immunosuppressive treatment. A randomized study of prophylaxis for 6 or 12 months after rituximab said a non-inferiority study is needed to compare those durations in patients with resolved HBV. Separately, a report notes that the association between chronic HBV and DLBCL prognosis remains controversial and describes HBV-associated liver failure after ibrutinib therapy.

Risk Across Lymphoma Subtypes

A 2019 report on a meta-analysis links HBV infection with increased risk of B-cell non-Hodgkin lymphoma, with the association especially noted for two subtypes. The supplied report does not name those subtypes or provide effect estimates, so more specific comparisons cannot be drawn from this source alone.

Furthermore, the study found that tenofovir was associated with a lower rate of acute hepatitis, a severe form of liver inflammation, compared to lamivudine. Patients receiving tenofovir were also less likely to experience disruptions in their chemotherapy treatment due to HBV-related complications. These findings suggest that tenofovir not only prevents HBV reactivation but also minimizes the risk of liver damage and treatment interruptions, ultimately improving the overall outcomes for lymphoma patients.

The Future of HBV Prevention in Lymphoma Patients

The study's findings provide compelling evidence for the superiority of tenofovir over lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy. However, the researchers emphasize the need for larger, more comprehensive studies to confirm these results and further investigate the long-term benefits and risks of tenofovir prophylaxis. Nevertheless, this research marks a significant step forward in optimizing the management of lymphoma patients who are also HBV carriers, offering hope for improved outcomes and a reduced risk of life-threatening complications.

AI Search Multiple angles on this topic

Prognosis and Evidence Gaps

A 2022 review reports that lymphoma patients with HBV infection have a poor prognosis, which may partly reflect delays or premature termination of antitumor treatment because of HBV reactivation. It also notes limited data on survival outcomes for HBV-related lymphoma in the era of prophylactic antivirals. A 2024 DLBCL meeting abstract reports that patients with chronic HBV infection (HBsAg-positive) have higher DLBCL risk, more unfavorable features at presentation, and worse survival than HBV-negative patients, while findings for past HBV infection are conflicting.

Questions for Further Research

A 2023 review reports that most B-NHL subtypes were found to be associated with HBV infection, with more than doubled risk identified for DLBCL, follicular lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, and precursor B lymphoblastic lymphoma. It reports no risk difference between germinal-center B-cell (GCB) and non-GCB patient groups. A 2025 meeting abstract says HBV is a common comorbidity in B-cell lymphoma, but its impact on long-term outcomes remains inadequately explored. Together, these reports point to an unresolved question about long-term outcomes across lymphoma subtypes.

Real-World DLBCL Experience

A 2024 real-world study focused on patients with pathologically diagnosed diffuse large B-cell lymphoma (DLBCL) who were infected with HBV. Its stated objective was to explore their clinical features and prognostic characteristics. The source notes that previous studies differ in their findings on clinical characteristics and prognostic factors, underscoring the importance of examining outcomes in real-world patient groups.

What the prevention figures show

The comparison with no prophylaxis helps put the relative ranking in context: both antiviral approaches were associated with lower odds of reactivation, and the estimate favored tenofovir. This is evidence from a network meta-analysis, not a direct head-to-head clinical trial of all five antiviral agents.[1]

A separate comparison found fewer reactivations and fewer cases of HBV-related and severe hepatitis during chemotherapy in the prophylaxis group. These results concern events during treatment; they do not establish that prophylaxis prevents later reactivation.[2]

What prevention comparisons still need to establish

  • Would direct clinical comparisons of the antiviral agents confirm the ranking seen in the network analysis? The source notes that systematic comparison has been limited by the lack of head-to-head trials.[1]
  • Do preventive effects persist after chemotherapy ends? The reported groups did not differ in post-chemotherapy reactivation, and HBV-reactivation-related hepatitis deaths occurred after protocol treatment in the prophylaxis group.[2]

Sources

  1. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation (pmc.ncbi.nlm.nih.gov)
  2. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What does Hepatitis B reactivation mean, and why is it a concern for lymphoma patients?

Hepatitis B reactivation refers to the resurgence of the Hepatitis B virus (HBV) in individuals who are carriers of the virus, especially when their immune system is weakened. This is significant because, for lymphoma patients undergoing chemotherapy, the treatment can suppress their immune system, making them vulnerable to HBV reactivation. Reactivation can lead to severe liver damage, potentially disrupting cancer treatment and causing life-threatening complications. Preventing this is crucial for ensuring the best possible outcome for patients.

2

What is antiviral prophylaxis, and why is it used for lymphoma patients who carry Hepatitis B?

Antiviral prophylaxis involves the preventive use of antiviral medications to reduce the risk of viral infections or reactivations. In the context of lymphoma patients who are also HBV carriers, antiviral prophylaxis is used to prevent the Hepatitis B virus from reactivating during chemotherapy. This is important because chemotherapy can weaken the immune system, allowing HBV to replicate and cause liver damage. Using antivirals like Tenofovir or Lamivudine can suppress the virus and protect the liver during cancer treatment.

3

What are Tenofovir and Lamivudine, and why are they important for lymphoma patients with Hepatitis B?

Tenofovir and Lamivudine are antiviral medications used to suppress the Hepatitis B virus (HBV). They are significant in the context of lymphoma patients undergoing chemotherapy because these patients are at risk of HBV reactivation, which can cause severe liver damage. Tenofovir and Lamivudine work by inhibiting the replication of HBV, thus preventing reactivation and protecting the liver. Tenofovir has been shown to be more effective than Lamivudine in preventing HBV reactivation, which makes it a more favorable option for these patients.

4

What is Diffuse Large B-Cell Lymphoma (DLBCL), and why is it relevant in the context of Hepatitis B?

Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma, which is a cancer of the lymphatic system. It's important when discussing Hepatitis B because patients with DLBCL often undergo chemotherapy, which can suppress the immune system and increase the risk of Hepatitis B virus (HBV) reactivation in those who are carriers. Understanding the connection between DLBCL, chemotherapy, and HBV is crucial for managing treatment and preventing complications such as liver damage.

5

What did the study find when comparing Tenofovir and Lamivudine, and why is this significant?

The study compared Tenofovir and Lamivudine. The key finding was that Tenofovir was more effective than Lamivudine in preventing Hepatitis B virus (HBV) reactivation in lymphoma patients undergoing chemotherapy. This is significant because it helps guide clinicians in choosing the most effective antiviral prophylaxis strategy to protect these vulnerable patients from liver damage and treatment interruptions. Using Tenofovir can significantly reduce the risk of HBV reactivation compared to Lamivudine, leading to better outcomes.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.